Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

ACRS – Aclaris Therapeutics Inc

Float Short %

7.1

Margin Of Safety %

Put/Call OI Ratio

0.02

EPS Next Q Diff

-0.01

EPS Last/This Y

1.18

EPS This/Next Y

-0.1

Price

1.8

Target Price

7.86

Analyst Recom

1.29

Performance Q

42.86

Relative Volume

0.5

Beta

0.27

Ticker: ACRS




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-25ACRS1.70.010.004662
2025-07-28ACRS1.690.010.004745
2025-07-29ACRS1.5550.010.004856
2025-07-30ACRS1.5350.010.004844
2025-07-31ACRS1.5350.010.014778
2025-08-01ACRS1.5350.011.114848
2025-08-04ACRS1.5550.010.004851
2025-08-05ACRS1.5450.010.004842
2025-08-06ACRS1.550.010.004912
2025-08-07ACRS1.580.010.204924
2025-08-08ACRS1.6350.010.004938
2025-08-11ACRS1.640.010.084938
2025-08-12ACRS1.6450.010.084938
2025-08-13ACRS1.7050.010.004945
2025-08-14ACRS1.6850.010.764947
2025-08-15ACRS1.8650.010.214972
2025-08-18ACRS1.8550.020.002340
2025-08-19ACRS1.7950.020.002356
2025-08-20ACRS1.8050.020.002357
2025-08-21ACRS1.7550.020.002377
2025-08-22ACRS1.7950.020.002375
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-25ACRS1.706.7- -0.58
2025-07-28ACRS1.706.7- -0.53
2025-07-29ACRS1.5514.5- -0.53
2025-07-30ACRS1.5314.5- -0.53
2025-07-31ACRS1.5314.5- -0.53
2025-08-01ACRS1.5314.5- -0.53
2025-08-04ACRS1.5614.5- -0.53
2025-08-05ACRS1.5514.5- -0.53
2025-08-06ACRS1.5614.5- -0.53
2025-08-07ACRS1.5714.5- -0.53
2025-08-08ACRS1.6314.5- -0.53
2025-08-11ACRS1.6414.5- -0.53
2025-08-12ACRS1.6414.5- -0.53
2025-08-13ACRS1.7014.5- -0.53
2025-08-14ACRS1.6814.5- -0.53
2025-08-15ACRS1.8714.5- -0.53
2025-08-18ACRS1.86-22.7- -0.53
2025-08-19ACRS1.79-22.7- -0.53
2025-08-20ACRS1.80-22.7- -0.53
2025-08-21ACRS1.76-22.7- -0.53
2025-08-22ACRS1.80-22.7- -0.53
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-25ACRS0.008.718.43
2025-07-28ACRS0.0013.218.43
2025-07-29ACRS0.0013.218.43
2025-07-30ACRS0.0013.218.43
2025-07-31ACRS0.0013.218.43
2025-08-01ACRS0.0013.218.43
2025-08-04ACRS0.0010.398.43
2025-08-05ACRS0.0010.398.43
2025-08-06ACRS0.0010.398.43
2025-08-07ACRS0.0010.398.43
2025-08-08ACRS0.0010.398.43
2025-08-11ACRS0.0010.388.43
2025-08-12ACRS0.0010.387.10
2025-08-13ACRS0.0010.387.10
2025-08-14ACRS0.0010.387.10
2025-08-15ACRS0.0010.387.10
2025-08-18ACRS0.009.367.10
2025-08-19ACRS0.009.367.10
2025-08-20ACRS0.009.367.10
2025-08-21ACRS0.009.367.10
2025-08-22ACRS0.009.367.10
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-0.13

Avg. EPS Est. Current Quarter

-0.14

Avg. EPS Est. Next Quarter

-0.14

Insider Transactions

Institutional Transactions

9.36

Beta

0.27

Average Sales Estimate Current Quarter

1

Average Sales Estimate Next Quarter

1

Fair Value

Quality Score

22

Growth Score

29

Sentiment Score

65

Actual DrawDown %

94.1

Max Drawdown 5-Year %

-97.8

Target Price

7.86

P/E

Forward P/E

PEG

P/S

11.61

P/B

1.48

P/Free Cash Flow

EPS

-1.37

Average EPS Est. Cur. Y​

-0.53

EPS Next Y. (Est.)

-0.63

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-802.03

Relative Volume

0.5

Return on Equity vs Sector %

-126.9

Return on Equity vs Industry %

-114

EPS 1 7Days Diff

EPS 1 30Days Diff

0.05

EBIT Estimation

Aclaris Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 61
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. Its Contract Research segment provides laboratory services. The company also develops ATI-1777, a soft JAK 1/3 inhibitor in Phase 2b trial for the treatment of atopic dermatitis and other dermatologic conditions; Bosakitug (ATI-045), an anti-TSLP monoclonal antibody in Phase 2a trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; Zunsemetinib (ATI-450), a mitogen-activated protein kinase-activated protein kinase 2 inhibitor under Phase 1b/2 trials for the treatment of metastatic breast cancer and pancreatic ductal adenocarcinoma; and ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in preclinical stage to treat various atopic, immunologic, and respiratory diseases, as well as an ITK selective inhibitor candidate for the treatment of autoimmune diseases. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
stock quote shares ACRS – Aclaris Therapeutics Inc Stock Price stock today
news today ACRS – Aclaris Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch ACRS – Aclaris Therapeutics Inc yahoo finance google finance
stock history ACRS – Aclaris Therapeutics Inc invest stock market
stock prices ACRS premarket after hours
ticker ACRS fair value insiders trading